Joseph Fraietta, PhD: Arming CAR T Cells for the Solid Tumor Battlefield

Years Funded: 2020-2022

Metabolic Reprogramming of the CAR T Cell Epigenome
At the University of Pennsylvania Perelman School of Medicine (Philadelphia, PA), Joseph Fraietta, PhD is collaborating with Naomi Haas, MD, to overcome prostate cancer’s stubborn resistance to CAR T-cell therapy. By unlocking the epigenetic code that controls the fate and function of T-cells, this research team expects to improve the success of T -cell therapy in inducing safe, long-term remission for advanced, metastatic prostate cancer.

Read More
Stephen Gottschalk, MD: I Never Need to Ask Myself Why I’m Here

Years Funded: 2020-2022

ECM-Targeted T-Cell Therapy
Building on past research breakthroughs, Stephen Gottschalk, MD, chair of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children’s Research Hospital (Memphis, TN), is moving a new approach to CAR T-cell therapy into clinical trials. Using two different gene protein biomarkers, Dr. Gottschalk expects to fortify a patient’s immune system to successfully attack and destroy sarcomas along with the blood vessels that support their growth.

Read More
Matthis Stephan, MD, PhD: Moving beyond Chemotherapy

Years Funded: 2018-2021

Preventing Cancer Vaccine Failure via Nanoparticle-Mediated TCR Programming
A multi-disciplinary team of immunologists, bioengineers and geneticists led by Matthias Stephan, MD, PhD, at the Fred Hutchinson Cancer Research Center (Seattle, WA) is advancing new strategies for fostering the effectiveness of anti-cancer vaccines in broad patient populations by combining principles of bioengineering and gene therapy.

Read More
Daniel J. Powell, Jr., PhD: An Optimistic Doctor

Years Funded: 2018-2021

Phase I Trial of Folate Receptor-Alpha CAR T-Cell Therapy for Solid Cancer
At the University of Pennsylvania Perelman School of Medicine (Philadelphia, PA), Daniel J. Powell, Jr., PhD, and colleagues are offering new hope to women battling advanced ovarian cancer. With a novel CAR T immunotherapy strategy, Dr. Powell uses genetic engineering to engage a patient’s existing immune system and enable it to recognize and destroy cancer.

Read More
Joseph Glorioso, III, MD, PhD: Turning Bad Guys into Good Guys

Years Funded: 2018-2020

Antigenic Stealthing of oHSV for Systemic Treatment of Melanoma
At the University of Pittsburgh (Pittsburgh, PA), Joseph Glorioso, III, MD, PhD, is pioneering creative new strategies to more safely and successfully target and triumph over melanoma and other metastatic cancers. His studies build on past successes in fighting solid tumors with viruses and a patient’s own immune system.

Read More

Join the Alliance

  • This field is for validation purposes and should be left unchanged.